Clinical Trial Update: TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing TCH versus EC-TH as neoadjuvant therapy for HER2-positive breast cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer with HER2 Overexpression

Drugs mentioned

• EC-TH (epirubicin, cyclophosphamide, trastuzumab, paclitaxel) (epirubicin, cyclophosphamide, trastuzumab, paclitaxel)
• TCH (docetaxel, carboplatin, trastuzumab) (docetaxel, carboplatin, trastuzumab)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: HER2-Positive Breast Cancer | Phase 2 | Status: COMPLETED